MAP2K7 and thyroid gland undifferentiated (anaplastic) carcinoma: Trametinib is an MEK inhibitor that inhibits the MEK and ERK signaling pathways and has been approved for use in the treatment of BRAF-mutant cancers, such as melanoma and anaplastic thyroid cancer, in combination with the BRAF inhibitor dabrafenib [37, 38].